The nab-paclitaxel/gemcitabine regimen for patients with refractory advanced pancreatic adenocarcinoma

Sofia Palacio, Peter Hosein, Isildinha Reis, Ikechukwu I. Akunyili, Vinicius Ernani, Terri Pollack, Jessica Macintyre, Maria H Restrepo, Jaime R Merchan, Caio M.Rocha Lima

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

The phase III MPACT trial for metastatic pancreatic cancer (PC) showed improved overall survival (OS), progression free survival (PFS) and response rates (RRs) for first-line nab-paclitaxel (Abraxane) and gemcitabine (the AG combination) compared to gemcitabine monotherapy. The safety and efficacy of the AG combination has not been systematically studied as second-line therapy or beyond for metastatic PC. We conducted an IRB-approved retrospective analysis of all patients diagnosed between September 2010 and August 2014 with advanced refractory PC that received combination treatment with AG at our institution. Demographic and survival data were extracted from the registry. Patients received nab-paclitaxel 125 mg/m2 and gemcitabine 1,000 mg/m2 and on days 1, 8 and 15 of a 28-day cycle with subsequent dose modifications based on tolerance. Data on 59 patients was available; the median age was 61; 55% were male; 56% received AG as second line therapy and 44% received it as third-line or beyond. Five (10%) patients had a confirmed partial response (PR), 23 (47%) had stable disease (SD) and 21 (43%) had disease progression as their best response. Among the 31 (52%) patients who received prior gemcitabine, 18 (58%) had clinical benefit; 3 had a PR and 15 had SD. The median OS was 3.9 months and the median progression-free survival was 3 months. Toxicity was similar to what was reported in the MPACT trial. This retrospective analysis suggests that AG is active in PC patients previously treated with either fluoropyrimidine-based therapy or gemcitabine-based therapy with manageable toxicities.

Original languageEnglish (US)
Pages (from-to)135-139
Number of pages5
JournalJournal of Gastrointestinal Oncology
Volume9
Issue number1
DOIs
StatePublished - Feb 1 2018

Fingerprint

gemcitabine
Adenocarcinoma
Pancreatic Neoplasms
Disease-Free Survival
Survival
Therapeutics
Research Ethics Committees
Registries
Disease Progression
130-nm albumin-bound paclitaxel
Survival Rate
Demography
Safety

Keywords

  • Albumin-bound paclitaxel
  • Gemcitabine
  • Pancreatic cancer (PC)

ASJC Scopus subject areas

  • Oncology
  • Gastroenterology

Cite this

The nab-paclitaxel/gemcitabine regimen for patients with refractory advanced pancreatic adenocarcinoma. / Palacio, Sofia; Hosein, Peter; Reis, Isildinha; Akunyili, Ikechukwu I.; Ernani, Vinicius; Pollack, Terri; Macintyre, Jessica; Restrepo, Maria H; Merchan, Jaime R; Lima, Caio M.Rocha.

In: Journal of Gastrointestinal Oncology, Vol. 9, No. 1, 01.02.2018, p. 135-139.

Research output: Contribution to journalArticle

Palacio, Sofia ; Hosein, Peter ; Reis, Isildinha ; Akunyili, Ikechukwu I. ; Ernani, Vinicius ; Pollack, Terri ; Macintyre, Jessica ; Restrepo, Maria H ; Merchan, Jaime R ; Lima, Caio M.Rocha. / The nab-paclitaxel/gemcitabine regimen for patients with refractory advanced pancreatic adenocarcinoma. In: Journal of Gastrointestinal Oncology. 2018 ; Vol. 9, No. 1. pp. 135-139.
@article{0ebd94193e7c4966af972716421d65a8,
title = "The nab-paclitaxel/gemcitabine regimen for patients with refractory advanced pancreatic adenocarcinoma",
abstract = "The phase III MPACT trial for metastatic pancreatic cancer (PC) showed improved overall survival (OS), progression free survival (PFS) and response rates (RRs) for first-line nab-paclitaxel (Abraxane) and gemcitabine (the AG combination) compared to gemcitabine monotherapy. The safety and efficacy of the AG combination has not been systematically studied as second-line therapy or beyond for metastatic PC. We conducted an IRB-approved retrospective analysis of all patients diagnosed between September 2010 and August 2014 with advanced refractory PC that received combination treatment with AG at our institution. Demographic and survival data were extracted from the registry. Patients received nab-paclitaxel 125 mg/m2 and gemcitabine 1,000 mg/m2 and on days 1, 8 and 15 of a 28-day cycle with subsequent dose modifications based on tolerance. Data on 59 patients was available; the median age was 61; 55{\%} were male; 56{\%} received AG as second line therapy and 44{\%} received it as third-line or beyond. Five (10{\%}) patients had a confirmed partial response (PR), 23 (47{\%}) had stable disease (SD) and 21 (43{\%}) had disease progression as their best response. Among the 31 (52{\%}) patients who received prior gemcitabine, 18 (58{\%}) had clinical benefit; 3 had a PR and 15 had SD. The median OS was 3.9 months and the median progression-free survival was 3 months. Toxicity was similar to what was reported in the MPACT trial. This retrospective analysis suggests that AG is active in PC patients previously treated with either fluoropyrimidine-based therapy or gemcitabine-based therapy with manageable toxicities.",
keywords = "Albumin-bound paclitaxel, Gemcitabine, Pancreatic cancer (PC)",
author = "Sofia Palacio and Peter Hosein and Isildinha Reis and Akunyili, {Ikechukwu I.} and Vinicius Ernani and Terri Pollack and Jessica Macintyre and Restrepo, {Maria H} and Merchan, {Jaime R} and Lima, {Caio M.Rocha}",
year = "2018",
month = "2",
day = "1",
doi = "10.21037/jgo.2017.10.12",
language = "English (US)",
volume = "9",
pages = "135--139",
journal = "Journal of Gastrointestinal Oncology",
issn = "2078-6891",
publisher = "Pioneer Bioscience Publishing Company (PBPC)",
number = "1",

}

TY - JOUR

T1 - The nab-paclitaxel/gemcitabine regimen for patients with refractory advanced pancreatic adenocarcinoma

AU - Palacio, Sofia

AU - Hosein, Peter

AU - Reis, Isildinha

AU - Akunyili, Ikechukwu I.

AU - Ernani, Vinicius

AU - Pollack, Terri

AU - Macintyre, Jessica

AU - Restrepo, Maria H

AU - Merchan, Jaime R

AU - Lima, Caio M.Rocha

PY - 2018/2/1

Y1 - 2018/2/1

N2 - The phase III MPACT trial for metastatic pancreatic cancer (PC) showed improved overall survival (OS), progression free survival (PFS) and response rates (RRs) for first-line nab-paclitaxel (Abraxane) and gemcitabine (the AG combination) compared to gemcitabine monotherapy. The safety and efficacy of the AG combination has not been systematically studied as second-line therapy or beyond for metastatic PC. We conducted an IRB-approved retrospective analysis of all patients diagnosed between September 2010 and August 2014 with advanced refractory PC that received combination treatment with AG at our institution. Demographic and survival data were extracted from the registry. Patients received nab-paclitaxel 125 mg/m2 and gemcitabine 1,000 mg/m2 and on days 1, 8 and 15 of a 28-day cycle with subsequent dose modifications based on tolerance. Data on 59 patients was available; the median age was 61; 55% were male; 56% received AG as second line therapy and 44% received it as third-line or beyond. Five (10%) patients had a confirmed partial response (PR), 23 (47%) had stable disease (SD) and 21 (43%) had disease progression as their best response. Among the 31 (52%) patients who received prior gemcitabine, 18 (58%) had clinical benefit; 3 had a PR and 15 had SD. The median OS was 3.9 months and the median progression-free survival was 3 months. Toxicity was similar to what was reported in the MPACT trial. This retrospective analysis suggests that AG is active in PC patients previously treated with either fluoropyrimidine-based therapy or gemcitabine-based therapy with manageable toxicities.

AB - The phase III MPACT trial for metastatic pancreatic cancer (PC) showed improved overall survival (OS), progression free survival (PFS) and response rates (RRs) for first-line nab-paclitaxel (Abraxane) and gemcitabine (the AG combination) compared to gemcitabine monotherapy. The safety and efficacy of the AG combination has not been systematically studied as second-line therapy or beyond for metastatic PC. We conducted an IRB-approved retrospective analysis of all patients diagnosed between September 2010 and August 2014 with advanced refractory PC that received combination treatment with AG at our institution. Demographic and survival data were extracted from the registry. Patients received nab-paclitaxel 125 mg/m2 and gemcitabine 1,000 mg/m2 and on days 1, 8 and 15 of a 28-day cycle with subsequent dose modifications based on tolerance. Data on 59 patients was available; the median age was 61; 55% were male; 56% received AG as second line therapy and 44% received it as third-line or beyond. Five (10%) patients had a confirmed partial response (PR), 23 (47%) had stable disease (SD) and 21 (43%) had disease progression as their best response. Among the 31 (52%) patients who received prior gemcitabine, 18 (58%) had clinical benefit; 3 had a PR and 15 had SD. The median OS was 3.9 months and the median progression-free survival was 3 months. Toxicity was similar to what was reported in the MPACT trial. This retrospective analysis suggests that AG is active in PC patients previously treated with either fluoropyrimidine-based therapy or gemcitabine-based therapy with manageable toxicities.

KW - Albumin-bound paclitaxel

KW - Gemcitabine

KW - Pancreatic cancer (PC)

UR - http://www.scopus.com/inward/record.url?scp=85041715671&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041715671&partnerID=8YFLogxK

U2 - 10.21037/jgo.2017.10.12

DO - 10.21037/jgo.2017.10.12

M3 - Article

AN - SCOPUS:85041715671

VL - 9

SP - 135

EP - 139

JO - Journal of Gastrointestinal Oncology

JF - Journal of Gastrointestinal Oncology

SN - 2078-6891

IS - 1

ER -